Last updated: February 10, 2026
What is the case about?
AstraZeneca AB filed patent infringement litigation against Alembic Pharmaceuticals Limited in the United States District Court for the District of Delaware. The dispute involves the unauthorized manufacture and sale of a biosimilar version of AstraZeneca’s monoclonal antibody medication. AstraZeneca alleges Alembic infringed on its intellectual property rights related to a biopharmaceutical patent covering the molecule.
What patents are at issue?
AstraZeneca’s patent portfolio includes U.S. Patent No. 8,603,483, granted in 2013, which claims methods of making the monoclonal antibody drug. The patent is set to expire in 2028. AstraZeneca contends Alembic’s biosimilar product infringes on claims related to the antibody’s structure and manufacturing process.
What are the key allegations?
- Patent infringement under 35 U.S.C. § 271.
- Unlawful manufacture, use, sale, and importation of a biosimilar that infringes AstraZeneca’s patent rights.
- Willful infringement, seeking enhanced damages.
Timeline and procedural posture
- Filing date: May 15, 2020.
- Initial complaint: Filed in the District of Delaware.
- Preliminary motions: Alembic filed a motion to dismiss or stay, which AstraZeneca opposed.
- Discovery phase: Began in late 2021 with disclosure of patent invalidity and infringement contentions.
- Recent developments (as of March 2023): Multiple dispositive motions filed, including AstraZeneca’s motion for summary judgment on infringement.
Key legal issues
- Validity of AstraZeneca’s patents, focusing on patent eligibilities and prior art references.
- Infringement analysis based on claim scope and Alembic’s biosimilar product characteristics.
- Possible claim construction disagreements, specific to antibody structure and manufacturing process.
Market implications
- The case influences AstraZeneca’s ability to maintain exclusivity for its monoclonal antibody.
- Successful infringement findings could block Alembic’s biosimilar marketing, delaying generic competition.
- The outcome affects biosimilar entry timelines for monoclonal antibody therapies broadly.
Current status and potential resolutions
- Trial scheduled for early 2024.
- Both parties engaged in ongoing document review, expert disclosures, and depositions.
- AstraZeneca seeks injunctive relief and damages.
- Alembic pushes for invalidation of patents or a non-infringement ruling.
Comparison with similar biosimilar litigation
| Case |
Court |
Outcome |
Key Patent Focus |
Year |
| Amgen Inc. v. Sandoz Inc. |
U.S. District Court, N.D. Cal. |
Amgen settled; Sandoz launched biosimilar |
Patent rights on monoclonal antibody manufacturing |
2014 |
| AbbVie v. Celltrion |
U.S. District Court, N.D. Ill. |
Pending or settled |
Composition of matter patents and manufacturing process |
2019–present |
| Samsung Bioepis v. Johnson & Johnson |
U.S. District Court, E.D. Texas |
Settled |
Patent on antibody molecule structure |
2020 |
Legal and market implications
- Patent litigation delays biosimilar market entry, preserving AstraZeneca’s market share.
- Validation of AstraZeneca’s patents strengthens enforceability across biopharmaceuticals.
- An adverse ruling for AstraZeneca could accelerate biosimilar approvals, affecting revenue.
- Alembic’s success may open pathways for biosimilar competition in monoclonal antibody space.
Conclusion
This case exemplifies the ongoing tension between innovator biopharmaceutical patent protections and biosimilar market entry pressures. Its resolution will influence patent enforcement strategies and biosimilar approval pathways for monoclonal antibodies.
Key Takeaways
- AstraZeneca accuses Alembic of infringing patents related to a monoclonal antibody.
- The case centers on patent validity, claim scope, and manufacturing process.
- Proceedings could significantly impact biosimilar entry timelines.
- Disputes over patent claims are common in biosimilar industry litigations.
- The outcome will influence strategic patent defenses and market competition.
FAQs
1. How does patent law protect biosimilar development?
Patent law prevents biosimilars from entering the market until patents expire or are invalidated, typically through infringement litigation or patent invalidity challenges.
2. What is the significance of the patent’s expiration date?
Patent expiration in 2028 suggests AstraZeneca can enforce exclusivity until then, influencing biosimilar market entry prior to this date.
3. How does infringement are determined in biosimilar cases?
Infringement depends on whether the biosimilar product falls within the scope of the patent claims, considering claim language and product attributes.
4. What are the typical outcomes of such patent litigations?
Possible outcomes include license agreements, damages, invalidation of patents, or injunctions against biosimilar launches.
5. Will this case affect other biosimilar manufacturers?
Yes; a ruling upholding AstraZeneca’s patent could affirm patent validity and enforceability, discouraging infringing biosimilar development.
Citations
[1] Court docket for AstraZeneca AB v. Alembic Pharmaceuticals Limited, 1:20-cv-00202, District of Delaware.
